Antibodies, Neutralizing

• 

  Subject Areas on Research

  • 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity. 
  • A Bivalent Omicron-Containing Booster Vaccine against Covid-19. 
  • A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity. 
  • A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies. 
  • A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome. 
  • A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. 
  • A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface. 
  • A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. 
  • A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during In Vivo Adaptation. 
  • A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. 
  • A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice. 
  • A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralization. 
  • A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. 
  • A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen. 
  • A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. 
  • A genetically engineered, stem-cell-derived cellular vaccine. 
  • A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike. 
  • A laboratory-adapted HCV JFH-1 strain is sensitive to neutralization and can gradually escape under the selection pressure of neutralizing human plasma. 
  • A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. 
  • A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence. 
  • A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. 
  • A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice. 
  • A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. 
  • A single, continuous metric to define tiered serum neutralization potency against HIV. 
  • A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus. 
  • A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. 
  • A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. 
  • A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. 
  • ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. 
  • AIDS/HIV. Host controls of HIV neutralizing antibodies. 
  • ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. 
  • Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. 
  • Activation of decidual invariant natural killer T cells promotes lipopolysaccharide-induced preterm birth. 
  • Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. 
  • Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. 
  • Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. 
  • Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. 
  • Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. 
  • Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. 
  • Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization. 
  • Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. 
  • An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice. 
  • An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques. 
  • An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. 
  • An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses. 
  • An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. 
  • An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion. 
  • An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. 
  • An essential role of antibodies in the control of Chikungunya virus infection. 
  • An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults. 
  • Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. 
  • Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. 
  • Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease. 
  • Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. 
  • Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. 
  • Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. 
  • Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. 
  • Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development? 
  • Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. 
  • Antibody responses to the HIV-1 envelope high mannose patch. 
  • Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis. 
  • Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. 
  • Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity. 
  • Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. 
  • Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. 
  • Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. 
  • Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. 
  • Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. 
  • Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. 
  • B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses. 
  • B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity. 
  • B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. 
  • B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates. 
  • BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine. 
  • Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies. 
  • Beyond Viral Neutralization. 
  • Bispecific Antibodies Against HIV. 
  • Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium. 
  • Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein. 
  • Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. 
  • Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques. 
  • Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine. 
  • Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. 
  • Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. 
  • Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay. 
  • Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. 
  • Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. 
  • Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. 
  • Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. 
  • Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. 
  • Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. 
  • Broadly Neutralizing Antibodies and the Development of Vaccines. 
  • Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India. 
  • Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. 
  • Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. 
  • Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. 
  • CD169-mediated trafficking of HIV to plasma membrane invaginations in dendritic cells attenuates efficacy of anti-gp120 broadly neutralizing antibodies. 
  • COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. 
  • Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. 
  • Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. 
  • Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial. 
  • Characterization of Plasma Immunoglobulin G Responses in Elite Neutralizers of Human Cytomegalovirus. 
  • Characterization of Simian Immunodeficiency Virus Variants Anatomically Compartmentalized in Plasma and Milk in Chronically Infected African Green Monkeys. 
  • Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop. 
  • Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain. 
  • Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia. 
  • Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. 
  • Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice 
  • Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. 
  • Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. 
  • Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells. 
  • Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques. 
  • Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach. 
  • Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. 
  • Combination therapy with anti-HIV-1 antibodies maintains viral suppression. 
  • Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. 
  • Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. 
  • Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers. 
  • Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. 
  • Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. 
  • Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. 
  • Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants. 
  • Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques. 
  • Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques. 
  • Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV. 
  • Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. 
  • Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. 
  • Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5. 
  • Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models. 
  • Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. 
  • Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F. 
  • Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. 
  • Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform. 
  • Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. 
  • Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. 
  • Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. 
  • Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages. 
  • Cross-protective immunity to porcine reproductive and respiratory syndrome virus by intranasal delivery of a live virus vaccine with a potent adjuvant. 
  • Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. 
  • Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. 
  • DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques. 
  • DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. 
  • DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. 
  • DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. 
  • Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. 
  • Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus. 
  • Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies. 
  • Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles. 
  • Designing synthetic vaccines for HIV. 
  • Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system. 
  • Determination of neutralization activities by a new versatile assay using an HIV-1 genome carrying the Gaussia luciferase gene. 
  • Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. 
  • Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques. 
  • Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. 
  • Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer. 
  • Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. 
  • Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis. 
  • Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection. 
  • Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. 
  • Differential immune imprinting by influenza virus vaccination and infection in nonhuman primates. 
  • Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. 
  • Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. 
  • Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. 
  • Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. 
  • Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies. 
  • Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study. 
  • Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. 
  • Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. 
  • Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. 
  • Ebola virus antibody decay-stimulation in a high proportion of survivors. 
  • Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. 
  • Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. 
  • Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. 
  • Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination. 
  • Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies. 
  • Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. 
  • Efficient transplacental IgG transfer in women infected with Zika virus during pregnancy. 
  • Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. 
  • Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein. 
  • Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence. 
  • Eliminating antibody polyreactivity through addition of N-linked glycosylation. 
  • Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus. 
  • Engineering antibody-based molecules for HIV treatment and cure. 
  • Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins. 
  • Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. 
  • Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. 
  • Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. 
  • Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. 
  • Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus. 
  • Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. 
  • Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. 
  • Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. 
  • Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion. 
  • Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. 
  • Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children. 
  • Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus. 
  • Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model. 
  • Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies. 
  • Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. 
  • Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV. 
  • Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors. 
  • Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. 
  • Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. 
  • Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. 
  • Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. 
  • Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. 
  • Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. 
  • Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. 
  • Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus. 
  • Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. 
  • Functional interrogation and mining of natively paired human VH:VL antibody repertoires. 
  • Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. 
  • GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. 
  • Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. 
  • Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. 
  • Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. 
  • Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. 
  • Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. 
  • Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation. 
  • Glycopeptide epitope facilitates HIV-1 envelope specific humoral immune responses by eliciting T cell help. 
  • Glycoprotein 96 perpetuates the persistent inflammation of rheumatoid arthritis. 
  • Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. 
  • HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. 
  • HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy. 
  • HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope. 
  • HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site. 
  • HIV-1 Envelope Conformation, Allostery, and Dynamics. 
  • HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. 
  • HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. 
  • HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. 
  • HIV-1 Vpu restricts Fc-mediated effector functions in vivo. 
  • HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. 
  • HIV-1 envelope glycoprotein trimers display open quaternary conformation when bound to the gp41 membrane-proximal external-region-directed broadly neutralizing antibody Z13e1. 
  • HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. 
  • HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. 
  • HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. 
  • HIV-1 neutralizing antibodies: understanding nature's pathways. 
  • HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. 
  • HIV-Host Interactions: Implications for Vaccine Design. 
  • HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. 
  • HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. 
  • Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. 
  • Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. 
  • Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. 
  • Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. 
  • High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. 
  • High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. 
  • Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. 
  • Homologous and Heterologous Covid-19 Booster Vaccinations. 
  • Host controls of HIV broadly neutralizing antibody development. 
  • Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization. 
  • Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. 
  • Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. 
  • Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein. 
  • Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. 
  • Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. 
  • Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. 
  • Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. 
  • Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. 
  • Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. 
  • Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome. 
  • Immune checkpoint modulation enhances HIV-1 antibody induction. 
  • Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. 
  • Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. 
  • Immune correlates of protection for dengue: State of the art and research agenda. 
  • Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. 
  • Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. 
  • Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization. 
  • Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. 
  • Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. 
  • Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. 
  • Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. 
  • Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine. 
  • Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. 
  • Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design. 
  • Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. 
  • Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone. 
  • Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. 
  • Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. 
  • Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. 
  • Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy. 
  • Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. 
  • Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. 
  • In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity. 
  • Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. 
  • Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth. 
  • Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization. 
  • Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site. 
  • Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. 
  • Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. 
  • Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. 
  • Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials. 
  • Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector. 
  • Induction of immunity to human immunodeficiency virus type-1 by vaccination. 
  • Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later. 
  • Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma. 
  • Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. 
  • Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. 
  • Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. 
  • Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis. 
  • Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. 
  • Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. 
  • Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. 
  • Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. 
  • Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. 
  • International network for comparison of HIV neutralization assays: the NeutNet report II. 
  • International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. 
  • Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59®-adjuvanted pandemic 2009 H1N1 vaccine. 
  • Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. 
  • Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques. 
  • In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. 
  • Is developing an HIV-1 vaccine possible? 
  • Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields. 
  • Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum. 
  • Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. 
  • Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. 
  • Kernel-based logistic regression model for protein sequence without vectorialization. 
  • Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage. 
  • Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. 
  • LFA-1-specific therapy prolongs allograft survival in rhesus macaques. 
  • Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. 
  • Lessons from babies: inducing HIV-1 broadly neutralizing antibodies. 
  • Lessons learned from HIV-1 vaccine trials: new priorities and directions. 
  • Lessons learned from human HIV vaccine trials. 
  • Leukaemia hijacks a neural mechanism to invade the central nervous system. 
  • Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization. 
  • Long-primed germinal centres with enduring affinity maturation and clonal migration. 
  • Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. 
  • Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response. 
  • Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. 
  • Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. 
  • Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. 
  • Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. 
  • Maternal Immunity and Vaccination Influence Disease Severity in Progeny in a Novel Mast Cell-Deficient Mouse Model of Severe Dengue. 
  • Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. 
  • Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. 
  • Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies. 
  • Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. 
  • Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. 
  • Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. 
  • Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. 
  • Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling. 
  • Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. 
  • Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus. 
  • Modulation of HIV-1 immunity by adjuvants. 
  • Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies. 
  • Monocyte-derived CD40 expression is regulated by interferon-γ/interferon-γ receptor-1 pathway when acting as a bridge during their interaction with T cells and allogeneic endothelial cells. 
  • Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. 
  • Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. 
  • Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. 
  • Multimodal assessments of Zika virus immune pathophysiological responses in marmosets. 
  • Nebulized mRNA-Encoded Antibodies Protect Hamsters from SARS-CoV-2 Infection. 
  • Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. 
  • Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies. 
  • Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. 
  • Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. 
  • Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination. 
  • Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. 
  • Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. 
  • Neutralization tiers of HIV-1. 
  • Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. 
  • Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. 
  • Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals. 
  • Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. 
  • Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. 
  • Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model. 
  • Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. 
  • Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? 
  • Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. 
  • Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. 
  • Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. 
  • Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. 
  • New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. 
  • New approaches to HIV vaccine development. 
  • Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. 
  • Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. 
  • Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. 
  • Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. 
  • Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. 
  • Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. 
  • Oral polio vaccine response in the MAL-ED birth cohort study: Considerations for polio eradication strategies. 
  • Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. 
  • Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. 
  • Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. 
  • Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. 
  • Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. 
  • Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. 
  • Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. 
  • Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction. 
  • Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. 
  • Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques. 
  • Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. 
  • Phenotypic Correlates of HIV-1 Macrophage Tropism. 
  • Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. 
  • Placental Transfer of Respiratory Syncytial Virus Antibody Among HIV-Exposed, Uninfected Infants. 
  • Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. 
  • Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design. 
  • Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. 
  • Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. 
  • Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants. 
  • Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. 
  • Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults. 
  • Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. 
  • Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. 
  • Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. 
  • Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models. 
  • Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. 
  • Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. 
  • Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. 
  • Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. 
  • Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys. 
  • Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. 
  • Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. 
  • Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. 
  • Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. 
  • Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. 
  • Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. 
  • Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. 
  • Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. 
  • Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. 
  • Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy. 
  • Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy. 
  • Programming the magnitude and persistence of antibody responses with innate immunity. 
  • Progress in HIV-1 vaccine development. 
  • Progress in HIV-1 vaccine development. 
  • Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. 
  • Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques. 
  • Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. 
  • Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. 
  • Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. 
  • R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. 
  • RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. 
  • RAB11FIP5-Deficient Mice Exhibit Cytokine-Related Transcriptomic Signatures. 
  • Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. 
  • Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. 
  • Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period. 
  • Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys. 
  • Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. 
  • Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. 
  • Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. 
  • Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. 
  • Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1. 
  • Rational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination. 
  • Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. 
  • Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector. 
  • Recombinant Simian Varicella Virus-Simian Immunodeficiency Virus Vaccine Induces T and B Cell Functions and Provides Partial Protection against Repeated Mucosal SIV Challenges in Rhesus Macaques. 
  • Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques. 
  • Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. 
  • Reduction of peak viremia by an integration-defective SIV proviral DNA vaccine in rhesus macaques. 
  • Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. 
  • Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. 
  • Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls. 
  • Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. 
  • Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. 
  • Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. 
  • Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. 
  • Role of HIV membrane in neutralization by two broadly neutralizing antibodies. 
  • Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. 
  • SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. 
  • SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. 
  • SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. 
  • SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. 
  • SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. 
  • SIV infection duration largely determines broadening of neutralizing antibody response in macaques. 
  • SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. 
  • Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. 
  • Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. 
  • Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. 
  • Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. 
  • Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. 
  • Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. 
  • Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. 
  • Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). 
  • Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. 
  • Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. 
  • Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. 
  • Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. 
  • Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. 
  • Screening the interactions between HIV-1 neutralizing antibodies and model lipid surfaces. 
  • Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies. 
  • Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. 
  • Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. 
  • Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. 
  • Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. 
  • Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. 
  • Seroprevalence of antibodies against chikungunya virus in Singapore resident adult population. 
  • Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial. 
  • Severe Acute Respiratory Syndrome Coronavirus 2 Viremia Is Associated With Coronavirus Disease 2019 Severity and Predicts Clinical Outcomes. 
  • Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes. 
  • Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. 
  • Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes. 
  • Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. 
  • Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. 
  • Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection. 
  • Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. 
  • Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. 
  • Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection. 
  • Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. 
  • Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. 
  • State of the art: von Willebrand disease. 
  • Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. 
  • Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. 
  • Strategies for eliciting HIV-1 inhibitory antibodies. 
  • Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. 
  • Strategies to circumvent humoral immunity to adeno-associated viral vectors. 
  • Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. 
  • Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. 
  • Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. 
  • Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. 
  • Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. 
  • Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. 
  • Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage. 
  • Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. 
  • Structurally Mapping Antigenic Epitopes of Adeno-associated Virus 9: Development of Antibody Escape Variants. 
  • Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. 
  • Structure and immune recognition of trimeric pre-fusion HIV-1 Env. 
  • Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. 
  • Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. 
  • Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer. 
  • Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. 
  • Structure-Guided Molecular Grafting of a Complex Broadly Neutralizing Viral Epitope. 
  • Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies. 
  • Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. 
  • Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies. 
  • Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. 
  • Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. 
  • Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. 
  • Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. 
  • Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease. 
  • Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen. 
  • Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. 
  • Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. 
  • T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. 
  • Tandem bispecific broadly neutralizing antibody - a novel approach to HIV-1 treatment. 
  • Targeting endogenous kidney regeneration using anti-IL11 therapy in acute and chronic models of kidney disease. 
  • The CXCL10/CXCR3 Axis Promotes Disease Pathogenesis in Mice upon CVA2 Infection. 
  • The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. 
  • The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. 
  • The Impact of Sustained Immunization Regimens on the Antibody Response to Oligomannose Glycans. 
  • The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. 
  • The Presence and Anti-HIV-1 Function of Tenascin C in Breast Milk and Genital Fluids. 
  • The SARS-CoV-2 Spike variant D614G favors an open conformational state. 
  • The development of CD4 binding site antibodies during HIV-1 infection. 
  • The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells. 
  • The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. 
  • The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat. 
  • The humoral response to HIV-1: new insights, renewed focus. 
  • The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. 
  • The quest for an antibody-based HIV vaccine. 
  • The role of antibodies in HIV vaccines. 
  • The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization. 
  • Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. 
  • Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. 
  • Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. 
  • Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. 
  • Towards a population-based threshold of protection for COVID-19 vaccines. 
  • Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. 
  • Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. 
  • Tumor necrosis factor-α pathway plays a critical role in regulating interferon-γ induced protein-10 production in initial allogeneic human monocyte-endothelial cell interactions. 
  • Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. 
  • Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development. 
  • Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. 
  • V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. 
  • Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. 
  • Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. 
  • Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. 
  • Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. 
  • Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. 
  • Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. 
  • Vaccine with bacterium-like particles displaying HIV-1 gp120 trimer elicits specific mucosal responses and neutralizing antibodies in rhesus macaques. 
  • Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. 
  • Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans. 
  • Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. 
  • Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody. 
  • Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone. 
  • What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. 
  • Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? 
  • Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. 
  • c-FLIP maintains tissue homeostasis by preventing apoptosis and programmed necrosis. 
  • epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. 
  • mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. 
  • sCD44 overexpression increases intraocular pressure and aqueous outflow resistance. 
  • λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies. 
• 

  Keywords of People

  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Gunn, Michael Dee, Professor of Medicine, Integrative Immunobiology